SavedAdd your journal

Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2020 / Cilt: 30 - Sayı: 3

Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?

Fatma BAŞAL
Ferit ASLAN
Guliz ZENGIN
İrem BİLGETEKİN
Ömür ÖKSÜZOĞLU
UMUT DEMİRCİ
Pages
180–189
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The median overall survival (OS) was 27 and 23.6 months and median progression-free survival (PFS) was 12.3 and 12.8 months in the CRT and consolidation treatment groups (p= 0.840 and 0.808), respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The role of consolidation chemotherapy is being investigated due to inconclusive outcomes, ascribed to high rates of recurrence and mortality with standard concurrent chemoradiotherapy (CRT) in patients with unresectable locally advanced non-small-cell lung cancer (LA-NSCLC).
📊
Key Findings & Data:In total, 136 patients with unresected LA-NSCLC were evaluated to identify and compare the factors influencing survival rates.
💡
Conclusion & Impact:The median overall survival (OS) was 27 and 23.6 months and median progression-free survival (PFS) was 12.3 and 12.8 months in the CRT and consolidation treatment groups (p= 0.840 and 0.808), respectively.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

The role of consolidation chemotherapy is being investigated due to inconclusive outcomes, ascribed to high rates of recurrence and mortality with standard concurrent chemoradiotherapy (CRT) in patients with unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). We evaluated the impact of consolidation chemotherapy on the survival of patients with LA-NSCLC at our single medical centre. In total, 136 patients with unresected LA-NSCLC were evaluated to identify and compare the factors influencing survival rates. The median overall survival (OS) was 27 and 23.6 months and median progression-free survival (PFS) was 12.3 and 12.8 months in the CRT and consolidation treatment groups (p= 0.840 and 0.808), respectively. Consolidation chemotherapy after concurrent CRT experiences has neither OS nor PFS survival benefit, compared with concurrent CRT alone. Thus, our study did not support favourable consolidation chemotherapy in patients with LA-NSCLC.

🔖

Cite This Article

BAŞAL, F., ASLAN, F., ZENGIN, G., BİLGETEKİN, İ., ÖKSÜZOĞLU, Ö., DEMİRCİ, U. (2020). Does Consolidation Chemotherapy improve Patient Survival in Locally Advanced Non-Small-Cell Lung Cancer?. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 30 - Sayı: 3, 180–189. https://ajindex.com/articles/323253

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018
  2. Reck M, Rabe KF. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N Engl J Med 377: 849-861, 2017
  3. Shlomi D, Ben-Avi R, Balmor GR, et al. Screening for lung cancer: time for large-scale screening by chest computed tomography. Eur Respir J 44: 217-238, 2014
  4. Wang X, Ding X, Kong D, et al. The effect of consolidation chemotherapy after concurrent chemoradiotherapy on the survival of patients with locally advanced non-small cell lung cancer: a meta-analysis. Int J Clin Oncol 22: 229-236, 2017
  5. Reich JM. A critical appraisal of overdiagnosis: estimates of its magnitude and implications for lung cancer screening. Thorax 63: 377-383, 2008
  6. Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc 94: 1623-1640, 2019
  7. Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 8: 1, 2017
  8. O’Rourke N, Figuls MRI, Bernadó NF, Macbeth F. Concurrent chemoradiotherapy in non‐small cell lung cancer. Cochrane Database of Systematic Reviews, 2010
  9. Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer: American College of Chest Physicians evidencebased clinical practice guidelines. Chest 143: e314S-e340S, 2013
  10. Urvay S, Yücel B. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a retrospective study. Ortadogu Medical Journal/Ortadogu Tip Dergisi 11: 40-46, 2019
  11. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non–small-cell lung cancer: The Hoosier Oncology Group and US Oncology. J Clin Oncol 26: 5755-5760, 2008
  12. Tsujino K, Kurata T, Yamamoto S, et al. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non–small-cell lung cancer?: A pooled analysis of the literature. J Thorac Oncol 8: 1181-1189, 2013
  13. Goldstraw P, Crowley J, Chanksy K, et al. Lung Cancer Staging Project: Proposals for the Revision of the TNM